Ratings Kerry Group plc London S.E.

Equities

KYGA

IE0004906560

Market Closed - London S.E. Other stock markets 11:35:06 2024-04-30 EDT			After market 15:58:00
78.8 ^EUR	-3.90%		81.08	+2.89%

04-02	Bernstein starts AstraZeneca at 'outperform'	AN
02-22	Transcript : Kerry Group plc Presents at 2024 Consumer Analyst Group of New York Conference, Feb-22-2024 10:00 AM

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Food Processing

	1st Jan change	Capi.	ESG Refinitiv
KERRY GROUP PLC	-0.38%	15.03B	-
NESTLÉ S.A.	-5.45%	265B	A-
MONDELEZ INTERNATIONAL, INC.	-0.68%	96.62B	C+
KRAFT HEINZ	+4.41%	46.98B	C+
DANONE	-0.03%	40.34B	B-
GENERAL MILLS, INC.	+8.17%	39.65B	B-
THE HERSHEY COMPANY	+4.01%	39.3B	B-
ARCHER-DANIELS-MIDLAND COMPANY	-18.78%	30.45B	B-
NESTLÉ INDIA LIMITED	-5.77%	29.01B	A
ASSOCIATED BRITISH FOODS PLC	+12.21%	24.9B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes